Tobin Abraham, MD
Endocrinology, Diabetes & Metabolism · Chestnut Hill, MANPI 1568629376
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 72.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $79 and has fallen 70.3% since, to $24 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MA, where the typical reported total is $583.
Across 7 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$95
- Radius Health, Inc.$24
- Medtronic$13
What the payments were for
- Food & beverage$131100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 5 | $95 |
| Radius Health, Inc. | 1 | $24 |
| Medtronic | 1 | $13 |
How this compares
$131 in reported general payments places this provider in the 25th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 381 | $439,243 |
| TrulicityDulaglutide | 300 | $325,636 |
| JardianceEmpagliflozin | 330 | $268,811 |
| OzempicSemaglutide | 222 | $247,390 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 147 | $60,770 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $52,629 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 327 | $45,658 |
| Teriparatide | 12 | $30,005 |
| JanuviaSitagliptin Phosphate | 30 | $27,279 |
| TradjentaLinagliptin | 30 | $26,980 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $24,140 |
| RybelsusSemaglutide | 14 | $22,738 |
| Humalog Kwikpen U-100Insulin Lispro | 85 | $22,174 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $20,745 |
| Novolog FlexpenInsulin Aspart | 58 | $14,908 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Chestnut Hill
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.